Keyword search (3,448 papers available)


Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.

Author(s): Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M

Int J Mol Sci. 2019 Dec 05;20(24): Authors: Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M

Article GUID: 31817343
The eIF2α Kinase GCN2 Modulates Period and Rhythmicity of the Circadian Clock by Translational Control of Atf4.

Author(s): Pathak SS, Liu D, Li T, de Zavalia N, Zhu L, Li J, Karthikeyan R, Alain T, Liu AC, Storch KF, Kaufman RJ, Jin VX, Amir S, Sonenberg N, Cao R

Neuron. 2019 Aug 26;: Authors: Pathak SS, Liu D, Li T, de Zavalia N, Zhu L, Li J, Karthikeyan R, Alain T, Liu AC, Storch KF, Kaufman RJ, Jin VX, Amir S, Sonenberg N, Cao R

Article GUID: 31522764
Light-regulated translational control of circadian behavior by eIF4E phosphorylation.

Author(s): Cao R, Gkogkas CG, de Zavalia N, Blum ID, Yanagiya A, Tsukumo Y, Xu H, Lee C, Storch KF, Liu AC, Amir S, Sonenberg N

Nat Neurosci. 2015 Jun;18(6):855-62 Authors: Cao R, Gkogkas CG, de Zavalia N, Blum ID, Yanagiya A, Tsukumo Y, Xu H, Lee C, Storch KF, Liu AC, Amir S, Sonenberg N

Article GUID: 25915475
Title:Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.
Authors:Subramaniyan Parimalam S,  Badilescu S,  Sonenberg N,  Bhat R,  Packirisamy M
Link:https://www.ncbi.nlm.nih.gov/pubmed/31817343?dopt=Abstract
DOI:10.3390/ijms20246126
Category:Int J Mol Sci
PMID:31817343
Dept Affiliation: ENCS
1 Optical-Bio Microsystems Laboratory, Micro-Nano-Bio Integration Center, Department of Mechanical and Industrial Engineering, Concordia University, Montreal, QC H3G 2W1, Canada.
2 Department of Biochemistry, McGill University, Montreal, QC H3A 1A3, Canada.
3 Department of Mechanical and Industrial Engineering, Concordia University, Montreal, QC H3G 2W1, Canada.

Description:

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.

Int J Mol Sci. 2019 Dec 05;20(24):

Authors: Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M

Abstract

There is a huge demand for pro-/anti-angiogenic nanomedicines to treat conditions such as ischemic strokes, brain tumors, and neurodegenerative diseases such as Alzheimer's and Parkinson's. Nanomedicines are therapeutic particles in the size range of 10-1000 nm, where the drug is encapsulated into nano-capsules or adsorbed onto nano-scaffolds. They have good blood-brain barrier permeability, stability and shelf life, and able to rapidly target different sites in the brain. However, the relationship between the nanomedicines' physical and chemical properties and its ability to travel across the brain remains incompletely understood. The main challenge is the lack of a reliable drug testing model for brain angiogenesis. Recently, microfluidic platforms (known as "lab-on-a-chip" or LOCs) have been developed to mimic the brain micro-vasculature related events, such as vasculogenesis, angiogenesis, inflammation, etc. The LOCs are able to closely replicate the dynamic conditions of the human brain and could be reliable platforms for drug screening applications. There are still many technical difficulties in establishing uniform and reproducible conditions, mainly due to the extreme complexity of the human brain. In this paper, we review the prospective of LOCs in the development of nanomedicines for brain angiogenesis-related conditions.

PMID: 31817343 [PubMed - in process]